CytoMed Therapeutics Limited (GDTC)

CytoMed Therapeutics Cash Flow Statement

Financials in millions SGD. Fiscal year is January - December.

Year	2023	2022	2021	2020
Net Income	-4.13	-3.13	-2.05	-1.94
Depreciation & Amortization	0.38	0.39	0.33	0.29
Other Operating Activities	0.22	1.34	0.01	0.79
Operating Cash Flow	-3.53	-1.4	-1.72	-0.85
Capital Expenditures	-0.06	-0.47	-0.58	-0.24
Acquisitions	0	0	-0.24	0
Change in Investments	-2.77	0	0	-0.25
Other Investing Activities	-	-	-	-0.02
Investing Cash Flow	-2.83	-0.47	-0.82	-0.51
Share Issuance / Repurchase	11.31	1.22	4	0.5
Debt Issued / Paid	-0.34	-0.13	0.29	1.49
Other Financing Activities	-0.05	-0.13	-0.12	-0.11
Financing Cash Flow	10.92	0.97	4.17	1.88
Exchange Rate Effect	-0.01	-0.03	-0.01	-0.01
Net Cash Flow	4.66	-0.9	1.64	0.52
Free Cash Flow	-3.59	-1.87	-2.3	-1.09
Free Cash Flow Per Share	-0.34	-0.24	-0.33	-0.19

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).